VISEN Pharmaceuticals Deepens Innovation at Source, Partners with XtalPi to Empower Endocrine Drug Discovery with AI

Source:财联社

On February 5, 2026, VISEN Pharmaceuticals (2561.HK) and XtalPi (2228.HK) jointly announced the achievement of a project agreement and long-term strategic cooperation. The overall scale of this collaboration reaches tens of millions of yuan, advancing in an orderly manner around the R&D stage objectives combined with key milestones. VISEN Pharmaceuticals has taken a crucial step in its strategy to explore new paradigms for R&D, aiming to deeply integrate XtalPi's cutting-edge technologies such as artificial intelligence (AI) into the source innovation process of its endocrine new drugs. It will continue to focus on indications and innovative targets in the field of endocrine metabolism with high clinical value, carry out early-stage new drug R&D work, and accelerate the construction of a more competitive product pipeline.

This collaboration represents VISEN Pharmaceuticals' precise strategic move to further enrich and deepen the breadth and depth of its product pipeline in the endocrinology and metabolism field, building upon its solid internal R&D capabilities and the introduction of a mature product pipeline. While continuously strengthening its internal R&D capacity and importing established pipelines, the company is proactively incorporating AI-driven original innovation as a key supplement. Through deep synergy with XtalPi's platform, VISEN Pharmaceuticals aims to break through the bottlenecks of efficiency and success rates inherent in traditional R&D models, injecting new and diversified innovative momentum into its product pipeline in the endocrinology and metabolism treatment area.

As an innovative pharmaceutical company focused on the field of endocrine therapy, VISEN Pharmaceuticals has established a full-chain layout covering research and development, production, and sales. Based on a deep understanding of the clinical needs in endocrine diseases and long-term pipeline development planning, VISEN Pharmaceuticals recognizes that to continuously lead innovation in this field and deepen its product pipeline in the area of endocrine metabolism, it is necessary to explore potential new targets, expand the range of indications, as well as iterate and upgrade the existing pipeline to enhance drug efficacy and safety. Introducing transformative tools like AI technology in the early discovery phase can provide new tools and possibilities to help achieve these two goals. According to CB Insights data, AI technology can reduce the time for drug discovery and preclinical research by nearly 40%, save 50%-60% of the time in the clinical trial phase, and lower R&D costs by approximately 16%.

Specifically, the mechanisms of endocrine and metabolic diseases are complex, especially for certain rare disease targets. Traditional research and development models face challenges such as long cycles and high uncertainty. To address this, VISEN Pharmaceuticals has actively evaluated and introduced AI drug discovery platforms that have been rigorously validated by top global pharmaceutical companies. For example, XtalPi is collaborating with 17 of the top 20 international pharmaceutical companies worldwide; its AI platform accelerated the development of Pfizer's COVID-19 oral drug PAXLOVID. Its ability to significantly enhance R&D certainty through a "computation + experimentation" closed loop aligns closely with VISEN Pharmaceuticals' goals of tackling complex targets and pursuing "best-in-class" drugs.

VISEN Pharmaceuticals (Shanghai) Co., Ltd. has chosen to collaborate with XtalPi this time, whose technical platform already possesses the mature experience of serving globally leading pharmaceutical enterprises. The cooperation between the two parties will focus on the field of endocrine and metabolic treatment, fully leveraging algorithm-generated...RobotExperimental validation combined with technical advantages, with the aim of achieving early discovery and optimization design of candidate new molecules, systematically reducing subsequent R&D risks.

In China's industrial environment, in recent years, the reform of the drug and medical device review and approval system has continued to deepen. With policy support, domestic pharmaceutical companies have shifted from simple technology introduction to deep integration with global top platforms, forming R&D capabilities with independent intellectual property rights, providing fertile ground for this kind of cross-border collaboration.

In the future, with the advancement of collaborative projects, more innovative drugs with clinical value are expected to emerge in the field of endocrinology and metabolism, providing patients with more treatment options. This collaboration, which focuses on niche sectors and leverages technological synergy to address R&D challenges, will also offer the industry more practical and globally relevant therapies inspired by innovation in China.